A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy

Niranjan Manoharan, Prem Sagar Subramanian

Research output: Contribution to journalArticle

Abstract

Purpose To report the first reported case of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of Harvoni (Gilead Sciences, Foster City, CA, USA), a newly approved treatment for Hepatitis C. Observations We report a case of NAION in a hepatitis C patient who completed Harvoni therapy just prior to presentation. Harvoni was suspected to be the causative agent given a lack of NAION risk factors in an otherwise healthy young patient. Conclusions NAION is an acute, painless vision loss that typically affects adults over 50. The mechanism of NAION remains uncertain although numerous associations have been identified including certain medications. Harvoni, a combination drug of ledipasvir/sofosbuvir, is a recently FDA-approved treatment for Hepatitis C. To date, however, no ophthalmological side effects have been reported with its use. Continued surveillance of patients treated with Harvoni will be needed to determine if additional events are observed in the future.

Original languageEnglish (US)
Pages (from-to)55-57
Number of pages3
JournalAmerican Journal of Ophthalmology Case Reports
Volume6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Keywords

  • Harvoni
  • Ischemic optic neuropathy
  • NAION

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy'. Together they form a unique fingerprint.

  • Cite this